Tearsheet

Allurion Technologies (ALUR)

Market Price (12/17/2025): $1.52 | Market Cap: $11.8 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Allurion Technologies (ALUR)

Market Price (12/17/2025): $1.52
Market Cap: $11.8 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Megatrend and thematic drivers Megatrends include Health & Wellness Trends, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Weight Management Solutions, Show more.	Weak multi-year price returns 2Y Excs Rtn is -141%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -41 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -238%
1			Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -50%, Rev Chg QQuarterly Revenue Change % is -50%
2			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -340%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -346%
3			Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 71%
4			High stock price volatility Vol 12M is 1818%
5			Key risks ALUR key risks include [1] securing critical FDA approval for its products, Show more.

0	Megatrend and thematic drivers Megatrends include Health & Wellness Trends, Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Weight Management Solutions, Show more.
1	Weak multi-year price returns 2Y Excs Rtn is -141%
2	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -41 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -238%
3	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -50%, Rev Chg QQuarterly Revenue Change % is -50%
4	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -340%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -346%
5	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 71%
6	High stock price volatility Vol 12M is 1818%
7	Key risks ALUR key risks include [1] securing critical FDA approval for its products, Show more.

Valuation, Metrics & Events

	12/17/25	2024	2023	2022	2021
Share Price CYE	$1.52	$0.43	$93.50
Market Cap CYE ($ Mil)	11.8	1.2	178.4	-	-
Total Debt ($ Mil)	33.4	37.9	41.9	59.5	26.1
Total Cash ($ Mil)	6.1	15.4	38.0	7.7	25.8
Enterprise Value ($ Mil)	39.1	39.1	220.3
Valuation Ratios
P/S TTM	0.9	0.0	0.1	0.0	0.0
P/EBIT TTM
P/E TTM	-0.5	-0.1	-0.1	0.0	0.0
Sector Ratios
P/S TTM (Sector)	11.4	10.5	8.0	5.0	10.4
P/EBIT TTM (Sector)	29.1	31.2	26.5	17.6	29.4
P/E TTM (Sector)	37.5	39.9	36.4	22.9	42.6

	12/17/25	2024	2023
Share Price CYE	$1.52	$0.43	$93.50
Market Cap CYE ($ Mil)	11.8	1.2	178.4
Total Debt ($ Mil)	33.4	37.9	41.9
Total Cash ($ Mil)	6.1	15.4	38.0
Enterprise Value ($ Mil)	39.1	39.1	220.3
Valuation Ratios
P/S TTM	0.9	0.0	0.1
P/EBIT TTM
P/E TTM	-0.5	-0.1	-0.1
Sector Ratios
P/S TTM (Sector)	11.4	10.5	8.0
P/EBIT TTM (Sector)	29.1	31.2	26.5
P/E TTM (Sector)	37.5	39.9	36.4

	ALUR	S&P 500
REVENUE GROWTH	VERY POOR
Rev LTM ($ Bil)	0.0
Rev Chg Q	-50.5%	7.3%
Rev Chg LTM	-50.5%	6.0%
Rev Chg 3Y Avg	-48.3%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.1
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-238.1%	18.8%
CFO/Rev LTM	-340.4%	20.4%
Net Inc Mgn	-187.9%	13.1%
VALUATION	VERY LOW
P/S	0.9	3.2
P/CFO	-0.3	16.0
P/FCF	-0.3	20.7
P/E	-0.5	23.5

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Total patients treated with the Allurion Program	nearly 20,000	6172025	Link
Cumulative patients treated with the Allurion balloon since 2016	over 150,000	8132024	Link
Quarterly Allurion balloon placements	over 10,000	8132024	Link
Growth in clinics piloting GLP-1 combination approach	20% increase compared to the first quarter of 2025	8052025	Link
Quarter-over-quarter and year-over-year growth in pilot clinics (B2B2C sales model)	40%	5202025	Link

Upcoming
3/25/2026	Earnings Release	Rev: - EPS: -

ALUR Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

1. Allurion Technologies reported a significant 50% year-over-year decrease in its Q3 2025 revenue, falling to $2.7 million from $5.4 million in the same period last year. This decline was primarily attributed to distributor transitions and reduced sales and marketing investments.

2. The company experienced a compression in its gross profit and margin in Q3 2025. Gross profit decreased to $1.3 million, and the gross margin fell to 49% from 58% in Q3 2024, mainly due to lower sales and reduced production volumes.

3. Allurion Technologies continued to incur substantial operating losses, reporting $9.6 million in Q3 2025. Despite narrowing the operating loss, expenses remained high relative to the company's revenue base.

4. The company implemented a restructuring in Q3 2025, which included a 65% workforce reduction, and announced a strategic pivot to refocus on certain weight loss solutions. These initiatives, while potentially beneficial long-term, imply near-term operational disruption and market volatility.

5. Allurion secured a $5 million private placement financing at $1.67 per share in November 2025. While this strengthened the company's financial position and aimed to eliminate outstanding debt, the pricing of the shares at $1.67 could have been perceived as a lower valuation or a signal of potential dilution to existing shareholders, especially if the stock was trading at a higher price previously.

Stock Movement Drivers

Fundamental Drivers

The -28.8% change in ALUR stock from 9/17/2025 to 12/17/2025 was primarily driven by a -13.6% change in the company's Total Revenues ($ Mil).

	9172025	12172025	Change
Stock Price ($)	2.12	1.51	-28.77%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	19.92	17.21	-13.60%
P/S Multiple	0.78	0.68	-12.34%
Shares Outstanding (Mil)	7.30	7.76	-6.33%
Cumulative Contribution			-29.06%

LTM = Last Twelve Months as of date shown

Market Drivers

9/17/2025 to 12/17/2025

	Return	Correlation
ALUR	-29.2%
Market (SPY)	1.9%	36.2%
Sector (XLV)	12.1%	12.5%

Fundamental Drivers

The -37.6% change in ALUR stock from 6/18/2025 to 12/17/2025 was primarily driven by a -62.4% change in the company's Shares Outstanding (Mil).

	6182025	12172025	Change
Stock Price ($)	2.42	1.51	-37.60%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	28.30	17.21	-39.20%
P/S Multiple	0.41	0.68	66.72%
Shares Outstanding (Mil)	4.78	7.76	-62.45%
Cumulative Contribution			-61.94%

LTM = Last Twelve Months as of date shown

Market Drivers

6/18/2025 to 12/17/2025

	Return	Correlation
ALUR	-38.0%
Market (SPY)	12.7%	36.2%
Sector (XLV)	16.0%	6.0%

Fundamental Drivers

The -80.8% change in ALUR stock from 12/17/2024 to 12/17/2025 was primarily driven by a -202.8% change in the company's Shares Outstanding (Mil).

	12172024	12172025	Change
Stock Price ($)	7.88	1.51	-80.84%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	34.75	17.21	-50.49%
P/S Multiple	0.58	0.68	17.16%
Shares Outstanding (Mil)	2.56	7.76	-202.82%
Cumulative Contribution			-159.65%

LTM = Last Twelve Months as of date shown

Market Drivers

12/17/2024 to 12/17/2025

	Return	Correlation
ALUR	-81.0%
Market (SPY)	12.1%	7.9%
Sector (XLV)	11.9%	5.8%

Fundamental Drivers

null
null

Market Drivers

12/18/2023 to 12/17/2025

	Return	Correlation
ALUR	-98.3%
Market (SPY)	44.9%	6.4%
Sector (XLV)	17.8%	4.9%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
ALUR Return	�	�	�	�	-100%	258%	�
Peers Return	13%	24%	0%	23%	28%	24%	173%
S&P 500 Return	16%	27%	-19%	24%	23%	14%	108%
Monthly Win Rates [3]
ALUR Win Rate	�	�	�	50%	25%	33%
Peers Win Rate	50%	52%	55%	52%	60%	63%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
ALUR Max Drawdown	�	�	�	�	-100%	-3%
Peers Max Drawdown	-30%	-7%	-23%	-11%	-3%	-8%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: BSX, MDT, JNJ, ISRG, LLY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/17/2025 (YTD)

How Low Can It Go

ALUR has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique Key	Event	XLV	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-16.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	19.1%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	599 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-28.8%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	40.4%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	116 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-15.8%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	18.8%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	326 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-40.6%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	68.3%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	1100 days	1480 days

Compare to

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Allurion Technologies (ALUR)

AI Generated Analysis | Feedback

Here are 1-2 brief analogies for Allurion Technologies:

The Invisalign for weight loss.
CoolSculpting for internal weight loss.

AI Generated Analysis | Feedback

Allurion Gastric Balloon: A non-surgical, swallowable balloon designed to temporarily fill a portion of the stomach, promoting feelings of fullness and aiding weight loss.
Allurion Program: A comprehensive weight-loss program that integrates the Allurion Gastric Balloon with digital health tools (connected scale, smartwatch, mobile app) and clinical support for sustained lifestyle changes.

AI Generated Analysis | Feedback

Allurion Technologies (ALUR) primarily sells its products and services to other companies, specifically healthcare providers, rather than directly to individuals.

Their major customers are not individual consumers but rather:

Medical clinics
Hospitals
Bariatric centers
Weight-loss specialty clinics
Individual healthcare professionals (who operate within or own the aforementioned types of clinics)

These entities purchase the Allurion Program components (such as the Allurion Gastric Balloon, smart scale, and access to their digital platform) to then offer the complete program to their own patients seeking weight management solutions.

Due to the distributed nature of their provider network across numerous countries and the typical business practices in the medical device industry, Allurion Technologies does not publicly disclose the names of specific "major customer companies" or individual clinic chains that would account for a significant portion of their revenue. Therefore, it is not possible to list specific customer company names and their stock symbols.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Shantanu Gaur, Chief Executive Officer and Co-Founder

Shantanu Gaur co-founded Allurion Technologies in 2009 while at Harvard Medical School with a mission to end obesity globally. He graduated summa cum laude from Harvard College with a B.S. in Biology and received his M.D. from Harvard Medical School, where he was recognized as a Paul Revere Frothingham Scholar and Paul & Daisy Soros Fellow. Gaur is an inventor on over 40 patents and has authored numerous peer-reviewed publications. Under his leadership, Allurion has treated over 100,000 patients, shedding over 2 million pounds, and achieved a 100%+ compound annual growth rate in revenues for seven years. Allurion went public on the New York Stock Exchange in August 2023.

Christopher Geberth, Former Chief Financial Officer

Christopher Geberth served as the Chief Financial Officer of Allurion Technologies from September 2020 until his resignation on November 13, 2024. Prior to joining Allurion, he was the Chief Financial Officer at Lutronic Inc., a medical equipment manufacturer, from December 2017 to September 2020. Before Lutronic, Geberth was the Executive Vice President of Finance at Cynosure, Inc., another medical equipment manufacturer, from June 2008 to December 2017. He holds a B.B.A. in Business from Pace University. As of November 13, 2024, CEO Shantanu Gaur temporarily assumed financial responsibilities.

Ram Chuttani M.D., Chief Medical Officer and Founding Partner

Ram Chuttani is the Chief Medical Officer and Founding Partner at Allurion Technologies. He previously served as Director of Endoscopy at Beth Israel Deaconess Medical Center and as a Professor at Brigham and Women's Hospital.

Ojas Buch, Chief Operating Officer

Ojas Buch serves as the Chief Operating Officer of Allurion Technologies.

Brendan Gibbons, Chief Legal Officer

Brendan Gibbons holds the position of Chief Legal Officer at Allurion Technologies.

AI Generated Analysis | Feedback

The key risks to Allurion Technologies (ALUR) primarily revolve around regulatory hurdles, intense market competition, and the company's financial viability.

Regulatory Approval and Commercialization: A primary risk for Allurion Technologies is its ability to obtain and maintain regulatory approvals, particularly the crucial U.S. Food and Drug Administration (FDA) approval for the Allurion Smart Capsule and Allurion Balloon. While the company has been advancing through FDA milestones, the successful commercialization of its products, especially in the significant U.S. market, is contingent upon securing and maintaining these approvals. The timing and outcome of these regulatory processes are critical for the company's market entry and future revenue generation.
Market Competition, particularly from GLP-1 Drugs: Allurion operates in a highly competitive and rapidly evolving obesity treatment market. A significant risk comes from the ongoing evolution of this market, particularly the increasing impact and adoption of GLP-1 (glucagon-like peptide-1) drugs. These pharmaceutical treatments represent a strong competitive force that could affect the demand for Allurion's non-surgical weight loss program. The company is exploring combination therapies with low-dose GLP-1s, indicating the competitive pressure from this class of drugs.
Financial Condition and Profitability: Allurion Technologies faces risks related to its financial performance and ability to achieve sustained profitability. Recent reports indicate challenges such as a decline in revenue and ongoing cash burn. Despite efforts to improve gross margins and reduce operating expenses, the company's financial metrics suggest difficulties in converting innovation into consistent profitability, which is essential for long-term growth and operational sustainability.

AI Generated Analysis | Feedback

The widespread adoption and increasing efficacy of GLP-1 receptor agonist drugs (such as semaglutide and tirzepatide, marketed as Ozempic, Wegovy, and Mounjaro) for weight loss pose a significant emerging threat to Allurion Technologies. These pharmaceutical interventions offer a highly effective, non-surgical, and increasingly accessible alternative for individuals seeking substantial weight reduction, directly competing with the market for medical devices like Allurion's Elipse balloon. The growing preference and prescribing trends for these drugs could reduce the addressable market and demand for device-based weight loss solutions.

AI Generated Analysis | Feedback

Allurion Technologies (ALUR) operates in the weight loss solutions market with its main products being the Allurion Balloon and the Allurion Virtual Care Suite (VCS). The addressable market for the intragastric balloon, which includes the Allurion Balloon, is substantial and growing: * The global intragastric balloon market was valued at $32.2 million in 2023. This market is projected to grow to $115.3 million by 2033, demonstrating a Compound Annual Growth Rate (CAGR) of 13.6% from 2024 to 2033. * Specifically, the North American intragastric balloon market was valued at $21.1 million in 2024, representing a dominant share of the global market. While the Allurion Virtual Care Suite is commercially available in the United States and used by providers in over 50 countries, specific monetary market sizing for this product was not identified.

AI Generated Analysis | Feedback

Allurion Technologies (ALUR) is poised for future revenue growth over the next 2-3 years, driven by several strategic initiatives and product advancements:

U.S. Market Entry: Allurion's Pre-Market Authorization (PMA) application for the Allurion Balloon has been accepted by the FDA, following positive topline results from its AUDACITY clinical trial. The company is actively preparing for a potential U.S. market launch, which is expected to be a significant driver of new revenue, possibly in 2026.
Combination Therapy with Low-Dose GLP-1s: Allurion is strategically pivoting to focus on combining its Allurion Program with low-dose GLP-1 (glucagon-like peptide-1) therapies. This approach aims to enhance weight loss, preserve muscle mass, and improve adherence to GLP-1 treatments, addressing limitations of GLP-1s alone. Initial pilot programs demonstrating a 20% growth in comprehensive obesity management program accounts compared to the prior quarter suggest strong potential for this new offering.
Expansion into New International Markets: The Allurion Program is currently registered in over 50 countries, and the company plans to launch in additional new international markets over the next three years, further extending its global reach and customer base.
Launch of Next-Generation Allurion Balloon Technology and Enhanced R&D Pipeline: Allurion has advanced its research and development pipeline, including securing new U.S. patents for an enhanced, next-generation version of its balloon technology, which is protected through April 2043. Additionally, the company has signed a term sheet with a strategic partner to potentially develop a novel GLP-1 drug-eluting intragastric balloon, indicating a commitment to product innovation.
Growth of the Virtual Care Suite (VCS) and Digital Health Tools: The Allurion Virtual Care Suite, which includes the Allurion Mobile App, the Iris AI Platform for healthcare providers (Allurion Insights), and the Allurion Connected Scale, forms a comprehensive digital ecosystem supporting its weight-loss program. AI product revenue from the Virtual Care Suite experienced an 82% year-over-year growth in the third quarter of 2024, indicating increasing adoption and revenue contribution from these digital solutions.

AI Generated Analysis | Feedback

Share Issuance

    Allurion Technologies became publicly listed in August 2023 through a business combination with Compute Health Acquisition Corp., issuing 37,812,000 shares to Allurion equityholders based on an assumed $500 million pro forma enterprise value.
    In February 2025, Allurion announced a registered direct offering to sell 900,000 shares of common stock for approximately $6.1 million in gross proceeds, alongside the issuance of warrants to purchase up to 1,800,000 shares in a concurrent private placement.
    In June 2024, the company launched an underwritten public offering to raise up to $20 million through the sale of common stock and warrants, with net proceeds intended for clinical trials, commercial sales, research and development, and general corporate purposes.


Inbound Investments

    The business combination in August 2023 resulted in approximately $100 million in net proceeds, including a Private Investment in Public Equity (PIPE) led by RTW Investments, equity contributions from Medtronic and Omar Ishrak, synthetic royalty financing, and a senior secured term loan from an affiliate of Fortress Investment Group.
    A $100 million Chardan Equity Facility (ChEF) was established as part of the SPAC merger, offering Allurion the flexibility to raise additional capital opportunistically post-closing.
    In January 2025, Allurion secured $2.5 million in gross proceeds through a private placement agreement with RTW Investments, which also included an option for up to an additional $10 million in funding tranches, aimed at extending the company's financial runway into early 2026.

Better Bets than Allurion Technologies (ALUR)

	ALUR	Better Performance than ALUR
Metric	Value	INDUSTRY: Life Sciences Tools & Services
Rev Chg LTM	-50.5%	NTRA (38.2%), A (4.5%), IQV (3.8%), TMO (3.2%), DHR (2.2%)
Op Mgn LTM	-238.1%	A (21.3%), DHR (19.0%), TMO (18.4%), IQV (14.2%), NTRA (-16.6%)
CFO/Rev LTM	-340.4%	DHR (26.0%), A (22.0%), IQV (17.6%), TMO (17.5%), NTRA (9.2%)
FCF/Rev LTM	-346.2%	DHR (20.7%), A (16.0%), TMO (14.0%), IQV (13.9%), NTRA (4.4%)
Total Yield	-203.1%	A (4.5%), IQV (4.0%), TMO (3.6%), DHR (2.5%), NTRA (-1.4%)
P/S	0.9	ARAY (0.4), VREX (0.6), INGN (0.6), OFIX (0.7), BVS (0.8)

	ALUR	Better Performance than ALUR
Metric	Value	SECTOR: Health Care
Rev Chg LTM	-50.5%	LLY (36.8%), UNH (10.5%), ABBV (7.4%), JNJ (5.1%), MRK (1.7%)
Op Mgn LTM	-238.1%	LLY (43.0%), MRK (34.9%), JNJ (26.2%), ABBV (24.1%), UNH (6.1%)
CFO/Rev LTM	-340.4%	ABBV (35.0%), MRK (26.6%), JNJ (26.3%), LLY (20.5%), UNH (4.8%)
FCF/Rev LTM	-346.2%	ABBV (33.0%), MRK (20.3%), JNJ (20.3%), UNH (4.0%), LLY (-0.1%)
Total Yield	-203.1%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), ABBV (3.4%), LLY (2.7%)
P/S	0.9	CVS (0.2), MCK (0.2), CI (0.3), ELV (0.4), UNH (0.7)

	ALUR	Better Performance than ALUR
Metric	Value	ALL OTHER SECTORS
Rev Chg LTM	-50.5%	NVDA (65.2%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%), AAPL (6.0%)
Op Mgn LTM	-238.1%	NVDA (58.8%), MSFT (46.3%), GOOGL (32.2%), AAPL (31.9%), AMZN (11.4%)
CFO/Rev LTM	-340.4%	MSFT (50.0%), NVDA (44.4%), GOOGL (39.3%), AAPL (26.6%), AMZN (18.1%)
FCF/Rev LTM	-346.2%	NVDA (41.3%), MSFT (26.6%), AAPL (23.5%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	-203.1%	GOOGL (4.6%), MSFT (3.4%), AMZN (3.0%), AAPL (3.0%), NVDA (2.2%)
P/S	0.9	GM (0.3), FDX (0.6), UPS (0.8), ALL (0.9), DELL (0.9)

null

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Allurion Technologies Earnings Notes
2	Allurion Technologies Stock Drop Looks Sharp, But How Deep Can It Go?	Return

	Title
0	ARTICLES

Trade Ideas

Select past ideas related to ALUR. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	16.3%	16.3%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.1%	-7.1%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.6%	3.6%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	1.6%	1.6%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	14.1%	14.1%	-5.1%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	16.3%	16.3%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.1%	-7.1%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.6%	3.6%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	1.6%	1.6%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	14.1%	14.1%	-5.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
UDMY	Udemy	0.9	12.7%	-26.5%
TWO	Two Harbors Investment	1.2	12.1%	8.5%
IOVA	Iovance Biotherapeutics	0.9	12.0%	-65.9%
KOD	Kodiak Sciences	1.4	11.8%	171.1%
RXRX	Recursion Pharmaceuticals	2.1	11.4%	-30.8%
TTC	Toro	7.9	10.7%	2.0%
HUT	Hut 8	4.2	9.0%	96.0%
TPL	Texas Pacific Land	20.3	7.6%	-19.7%
AXGN	Axogen	1.5	7.0%	90.5%
SSII	SS Innovations International	1.1	6.7%	-25.6%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
NOW	ServiceNow	32.5	-80.0%	-85.2%
FDMT	4D Molecular Therapeutics	0.5	-20.1%	65.4%
IMNM	Immunome	1.7	-15.8%	86.3%
HNRG	Hallador Energy	0.7	-15.2%	51.2%
AMPX	Amprius Technologies	1.1	-14.6%	213.6%
BNTC	Benitec Biopharma	0.4	-13.1%	-14.6%
FLNC	Fluence Energy	2.4	-12.9%	16.9%
IMSR	Terrestrial Energy	0.7	-12.6%
BE	Bloom Energy	18.1	-12.1%	246.6%
BW	Babcock & Wilcox Enterprises	0.5	-12.1%	182.9%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	13.7	55.9%	-3.2%
PL	Planet Labs PBC	5.0	27.3%	307.7%
EEX	Emerald	0.9	25.9%	-2.8%
EVCM	EverCommerce	2.2	17.2%	10.4%
CNL	Collective Mining	1.1	15.8%	229.3%
ENVA	Enova International	4.1	15.8%	70.8%
IMVT	Immunovant	4.6	14.5%	8.9%
QURE	uniQure	1.3	14.3%	30.4%
INNV	InnovAge	0.8	14.2%	49.6%
PGEN	Precigen	1.2	13.4%	255.4%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
NOW	ServiceNow	32.5	-81.7%	-85.2%
RZLT	Rezolute	0.2	-81.6%	-59.0%
FRMI	Fermi	6.3	-41.1%
LENZ	LENZ Therapeutics	0.5	-34.6%	-43.3%
BETR	Better Home & Finance	0.5	-30.9%	292.0%
LWLG	Lightwave Logic	0.4	-29.5%	41.4%
APLD	Applied Digital	5.6	-29.0%	188.0%
CRWV	CoreWeave	31.4	-26.8%
WULF	TeraWulf	4.5	-26.6%	104.4%
BW	Babcock & Wilcox Enterprises	0.5	-26.5%	182.9%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
OLMA	Olema Pharmaceuticals	2.8	282.6%	459.2%
WVE	WAVE Life Sciences	2.7	128.5%	32.1%
ALMS	Alumis	0.8	89.8%	34.6%
NUVB	Nuvation Bio	2.9	82.4%	220.3%
SEMR	SEMrush	1.8	75.7%	-0.2%
TE	T1 Energy	0.8	70.4%
ANF	Abercrombie & Fitch	5.6	68.4%	-21.6%
CBLL	CeriBell	0.8	67.5%	-16.6%
FTRE	Fortrea	1.5	65.4%	-13.2%
VERA	Vera Therapeutics	3.1	64.7%	14.8%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
NOW	ServiceNow	32.5	-81.3%	-85.2%
RZLT	Rezolute	0.2	-80.3%	-59.0%
JANX	Janux Therapeutics	0.9	-50.9%	-73.7%
FRMI	Fermi	6.3	-50.6%
AGIO	Agios Pharmaceuticals	1.5	-43.6%	-22.6%
IMSR	Terrestrial Energy	0.7	-38.9%
LENZ	LENZ Therapeutics	0.5	-36.3%	-43.3%
LWLG	Lightwave Logic	0.4	-36.3%	41.4%
UAMY	United States Antimony	0.5	-33.7%	156.5%
BETR	Better Home & Finance	0.5	-33.6%	292.0%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
UDMY	Udemy	0.9	12.7%	-26.5%
TWO	Two Harbors Investment	1.2	12.1%	8.5%
IOVA	Iovance Biotherapeutics	0.9	12.0%	-65.9%
KOD	Kodiak Sciences	1.4	11.8%	171.1%
RXRX	Recursion Pharmaceuticals	2.1	11.4%	-30.8%
TTC	Toro	7.9	10.7%	2.0%
HUT	Hut 8	4.2	9.0%	96.0%
TPL	Texas Pacific Land	20.3	7.6%	-19.7%
AXGN	Axogen	1.5	7.0%	90.5%
SSII	SS Innovations International	1.1	6.7%	-25.6%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
NOW	ServiceNow	32.5	-80.0%	-85.2%
FDMT	4D Molecular Therapeutics	0.5	-20.1%	65.4%
IMNM	Immunome	1.7	-15.8%	86.3%
HNRG	Hallador Energy	0.7	-15.2%	51.2%
AMPX	Amprius Technologies	1.1	-14.6%	213.6%
BNTC	Benitec Biopharma	0.4	-13.1%	-14.6%
FLNC	Fluence Energy	2.4	-12.9%	16.9%
IMSR	Terrestrial Energy	0.7	-12.6%
BE	Bloom Energy	18.1	-12.1%	246.6%
BW	Babcock & Wilcox Enterprises	0.5	-12.1%	182.9%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TLRY	Tilray Brands	13.7	55.9%	-3.2%
PL	Planet Labs PBC	5.0	27.3%	307.7%
EEX	Emerald	0.9	25.9%	-2.8%
EVCM	EverCommerce	2.2	17.2%	10.4%
CNL	Collective Mining	1.1	15.8%	229.3%
ENVA	Enova International	4.1	15.8%	70.8%
IMVT	Immunovant	4.6	14.5%	8.9%
QURE	uniQure	1.3	14.3%	30.4%
INNV	InnovAge	0.8	14.2%	49.6%
PGEN	Precigen	1.2	13.4%	255.4%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
NOW	ServiceNow	32.5	-81.7%	-85.2%
RZLT	Rezolute	0.2	-81.6%	-59.0%
FRMI	Fermi	6.3	-41.1%
LENZ	LENZ Therapeutics	0.5	-34.6%	-43.3%
BETR	Better Home & Finance	0.5	-30.9%	292.0%
LWLG	Lightwave Logic	0.4	-29.5%	41.4%
APLD	Applied Digital	5.6	-29.0%	188.0%
CRWV	CoreWeave	31.4	-26.8%
WULF	TeraWulf	4.5	-26.6%	104.4%
BW	Babcock & Wilcox Enterprises	0.5	-26.5%	182.9%

Peer Comparisons for Allurion Technologies

Peers to compare with:

Financials

	ALUR	BSX	MDT	JNJ	ISRG	LLY	Median
Name	Allurion.	Boston S.	Medtronic	Johnson .	Intuitiv.	Eli Lilly
Mkt Price	1.51	94.55	98.39	210.56	557.21	1,041.56	154.47
Mkt Cap	0.0	140.1	126.1	507.1	198.7	935.2	169.4
Rev LTM	17	19,350	34,758	92,149	9,612	53,258	27,054
Op Inc LTM	-41	3,720	6,719	24,146	2,816	22,882	5,220
FCF LTM	-60	3,628	5,206	18,679	2,271	-50	2,950
FCF 3Y Avg	-57	2,378	4,917	17,814	1,371	-156	1,875
CFO LTM	-59	4,626	7,113	24,204	2,961	10,938	5,870
CFO 3Y Avg	-56	3,305	6,626	23,209	2,268	7,230	4,966

Growth & Margins

	ALUR	BSX	MDT	JNJ	ISRG	LLY	Median
Name	Allurion.	Boston S.	Medtronic	Johnson .	Intuitiv.	Eli Lilly
Rev Chg LTM	-50.5%	21.6%	5.3%	5.1%	22.2%	36.8%	13.5%
Rev Chg 3Y Avg	-	15.6%	4.1%	6.1%	16.3%	23.4%	15.6%
Rev Chg Q	-50.5%	20.3%	6.6%	6.8%	22.9%	37.6%	13.6%
QoQ Delta Rev Chg LTM	-13.6%	4.6%	1.6%	1.7%	5.1%	8.7%	3.2%
Op Mgn LTM	-238.1%	19.2%	19.3%	26.2%	29.3%	43.0%	22.8%
Op Mgn 3Y Avg	-168.6%	18.0%	18.6%	26.4%	26.7%	35.6%	22.5%
QoQ Delta Op Mgn LTM	-18.8%	0.9%	-0.1%	1.7%	0.5%	1.8%	0.7%
CFO/Rev LTM	-340.4%	23.9%	20.5%	26.3%	30.8%	20.5%	22.2%
CFO/Rev 3Y Avg	-191.8%	19.8%	19.9%	26.4%	27.8%	17.8%	19.9%
FCF/Rev LTM	-346.2%	18.7%	15.0%	20.3%	23.6%	-0.1%	16.9%
FCF/Rev 3Y Avg	-195.5%	14.1%	14.8%	20.3%	16.5%	0.5%	14.4%

Valuation

	ALUR	BSX	MDT	JNJ	ISRG	LLY	Median
Name	Allurion.	Boston S.	Medtronic	Johnson .	Intuitiv.	Eli Lilly
Mkt Cap	0.0	140.1	126.1	507.1	198.7	935.2	169.4
P/S	0.9	7.5	3.6	4.9	16.6	12.9	6.2
P/EBIT	-	40.1	19.7	13.8	56.7	38.5	38.5
P/E	-0.5	51.8	26.5	17.8	58.1	49.6	38.1
P/CFO	-0.3	31.3	17.7	18.5	53.9	62.6	24.9
Total Yield	-203.1%	1.9%	6.6%	8.4%	1.7%	2.7%	2.3%
Dividend Yield	0.0%	0.0%	2.9%	2.7%	0.0%	0.7%	0.4%
FCF Yield 3Y Avg	-	2.0%	4.3%	4.4%	1.0%	0.1%	2.0%
D/E	-	0.1	0.2	0.1	0.0	0.1	0.1
Net D/E	-	0.1	0.2	0.1	-0.0	0.1	0.1

Returns

	ALUR	BSX	MDT	JNJ	ISRG	LLY	Median
Name	Allurion.	Boston S.	Medtronic	Johnson .	Intuitiv.	Eli Lilly
1M Rtn	7.9%	-7.1%	2.2%	6.2%	1.9%	1.9%	2.1%
3M Rtn	-28.8%	-4.0%	4.8%	19.6%	28.5%	37.2%	12.2%
6M Rtn	-37.6%	-6.7%	16.6%	41.6%	9.4%	33.2%	13.0%
12M Rtn	-80.8%	4.6%	24.9%	48.2%	2.2%	34.8%	14.7%
3Y Rtn	-	106.4%	41.6%	31.3%	110.5%	196.4%	106.4%
1M Excs Rtn	7.1%	-7.8%	1.5%	5.4%	1.2%	1.2%	1.3%
3M Excs Rtn	-27.7%	-5.1%	2.4%	20.3%	26.5%	35.4%	11.3%
6M Excs Rtn	-50.1%	-19.1%	4.2%	29.2%	-3.0%	20.8%	0.6%
12M Excs Rtn	-93.7%	-6.2%	12.1%	36.9%	-7.8%	21.9%	3.0%
3Y Excs Rtn	-	32.1%	-32.2%	-38.8%	35.0%	122.0%	32.1%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Filing Date	11/17/2025	3/27/2025	3/26/2024	7/7/2023	2/14/2023
Key Financials
Total Revenue	17	32	53	64	38
EBITDA	-31	-3	-71	-32	-8
Operating Income	-41	-50	-79	-32	-13
Net Income	-32	-7	-83	-38	-12
EPS	-11.07	-3.20	-59.38	-21.85	-7.33
Growth Rates
Total Revenue Growth	-50.5%	-39.9%	-16.7%	67.9%	-
EBITDA Growth	-154.5%	95.1%	-120.7%	-302.9%	-
Operating Income Growth	30.3%	36.5%	-147.0%	-156.1%	-
Net Income Growth	-70.3%	91.3%	-119.4%	-204.7%	-
Margins
EBITDA Margin	-179.3%	-10.8%	-133.2%	-50.3%	-20.9%
Operating Income Margin	-238.1%	-156.3%	-147.9%	-49.9%	-32.7%
Net Income Margin	-187.9%	-22.4%	-154.9%	-58.8%	-32.4%
Cash & Debt
Total Cash	6	15	38	8	26
Total Debt	33	38	42	60	26
Net Debt / (Cash)	27	23	4	52	0
Cash Flows
Net Cash from Operations	-59	-64	-64	-47	-14
Free Cash from Operations	-60	-66	-66	-49	-15
Returns to Shareholders
Dividends	0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0

null

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021
Single Segment	32	53	64	38
Total	32	53	64	38

Operating Income by Segment

$ Mil	2024	2023	2022	2021
Single Segment		-79
Total		-79

Net Income by Segment

$ Mil	2024	2023	2022	2021
Single Segment	-7	-81
Total	-7	-81

Price Behavior

Price Behavior

Market Price	$1.50
Market Cap ($ Bil)	0.0
First Trading Date	08/02/2023
Distance from 52W High	-86.1%
	50 Days	200 Days
DMA Price	$1.70	$2.34
DMA Trend	down	down
Distance from DMA	-11.6%	-35.8%
	3M	1YR
Volatility	103.4%	1,829.1%
Downside Capture	344.35	646.58
Upside Capture	139.80	425.22
Correlation (SPY)	35.9%	8.0%

ALUR Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	5.03	3.11	3.16	2.78	7.28	3.48
Up Beta	7.39	4.26	4.12	3.88	6.97	-5.16
Down Beta	16.58	5.09	4.50	3.14	2.89	-2.51
Up Capture	161%	81%	104%	108%	3232%	83%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	7	17	26	53	101	239
Down Capture	307%	249%	276%	264%	170%	112%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	11	23	35	66	134	320

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

null

Based On 5-Year Data

null

Based On 10-Year Data

null

Short Interest

Short Interest: As Of Date	11282025
Short Interest: Shares Quantity	549,490
Short Interest: % Change Since 11152025	23.2%
Average Daily Volume	190,247
Days-to-Cover Short Interest	2.89
Basic Shares Quantity	7,762,703
Short % of Basic Shares	7.1%

Returns Analyses

	Title
0	Allurion Technologies Stock Drop Looks Sharp, But How Deep Can It Go?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
11/12/2025	0.7%	-4.7%	12.1%
8/7/2025	-2.9%	-9.8%	-21.0%
3/26/2025	0.3%	6.4%	-25.1%
11/13/2024	-26.3%	-42.3%	-51.4%
8/13/2024	-2.1%	-16.5%	-22.0%
3/21/2024	-4.3%	-16.2%	-5.2%
11/13/2023	1.7%	2.4%	-19.2%
SUMMARY STATS
# Positive	3	2	1
# Negative	4	5	6
Median Positive	0.7%	4.4%	12.1%
Median Negative	-3.6%	-16.2%	-21.5%
Max Positive	1.7%	6.4%	12.1%
Max Negative	-26.3%	-42.3%	-51.4%

	Forward Returns
11/12/2025	0.7%	-4.7%	12.1%
8/7/2025	-2.9%	-9.8%	-21.0%
3/26/2025	0.3%	6.4%	-25.1%
11/13/2024	-26.3%	-42.3%	-51.4%
8/13/2024	-2.1%	-16.5%	-22.0%
3/21/2024	-4.3%	-16.2%	-5.2%
11/13/2023	1.7%	2.4%	-19.2%
SUMMARY STATS
# Positive	3	2	1
# Negative	4	5	6
Median Positive	0.7%	4.4%	12.1%
Median Negative	-3.6%	-16.2%	-21.5%
Max Positive	1.7%	6.4%	12.1%
Max Negative	-26.3%	-42.3%	-51.4%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11172025	10-Q 9/30/2025
6302025	8192025	10-Q 6/30/2025
3312025	5152025	10-Q 3/31/2025
12312024	3272025	10-K 12/31/2024
9302024	11132024	10-Q 9/30/2024
6302024	8142024	10-Q 6/30/2024
3312024	5142024	10-Q 3/31/2024
12312023	3262024	10-K 12/31/2023
9302023	11142023	10-Q 9/30/2023
6302023	10202023	10-Q 6/30/2023
12312022	7072023	424B3 12/31/2022
12312021	2142023	DRS 12/31/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Allurion Technologies (ALUR)

Market Price (12/17/2025): $1.52 | Market Cap: $11.8 MilSector: Health Care | Industry: Life Sciences Tools & Services

Allurion Technologies (ALUR)

Market Price (12/17/2025): $1.52Market Cap: $11.8 MilSector: Health CareIndustry: Life Sciences Tools & Services

Valuation, Metrics & Events

ALUR Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Allurion Technologies (ALUR)

Share Issuance

Inbound Investments

Interactive Breakdown

Better Bets than Allurion Technologies (ALUR)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Allurion Technologies

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/17/2025): $1.52 | Market Cap: $11.8 Mil
Sector: Health Care | Industry: Life Sciences Tools & Services

Market Price (12/17/2025): $1.52
Market Cap: $11.8 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services